The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with a major lack of transparency about how savings are used to benefit patients. As HRSA launches a new rebate-based model meant to boost oversight, experts warned that it could instead burden smaller providers and fail to address the program’s deeper flaws.
The post The 340B Program’s New Rebate Pilot Won’t Fix Its Problems appeared first on MedCity News.
